The therapeutic potential of DPP4 inhibitors was confirmed in an observational study by Chang et al. involving more than 90,000 patients with diabetes, in which the addition of a DPP-4 inhibitor as a second-line antidiabetic treatment reduced the onset of AF by 35% [27]. Here, DPP4 is linked to atrial fibrillation.